Literature DB >> 20026797

Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study.

Yoshihiro Nishida, Satoshi Tsukushi, Yoji Shido, Junji Wasa, Naoki Ishiguro, Yoshihisa Yamada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20026797     DOI： 10.1200/JCO.2009.25.5950

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  31 in total

1.  Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan.

Authors:  Yoshihiro Nishida; Akira Kawai; Junya Toguchida; Akira Ogose; Keisuke Ae; Toshiyuki Kunisada; Yoshihiro Matsumoto; Tomoya Matsunobu; Kunihiko Takahashi; Kazuki Nishida; Toshifumi Ozaki
Journal:  Int J Clin Oncol       Date:  2019-07-22       Impact factor: 3.402

2.  Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors.

Authors:  Nicholas A Mignemi; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Hernan Correa; Cheryl M Coffin; Jennifer O Black; Yajun Yi; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Jonathan G Schoenecker; Justin M M Cates
Journal:  Cancer Sci       Date:  2012-11-15       Impact factor: 6.716

3.  Successful management of aggressive fibromatosis of the neck using wide surgical excision: a case report.

Authors:  Zain A Sobani; Montasir Junaid; Mumtaz J Khan
Journal:  J Med Case Rep       Date:  2011-06-27

4.  Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status.

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Hiroshi Urakawa; Shunsuke Hamada; Eiji Kozawa; Kunihiro Ikuta; Yuichi Ando; Naoki Ishiguro
Journal:  Int J Clin Oncol       Date:  2015-04-22       Impact factor: 3.402

5.  Nuclear expression of β-catenin predicts the efficacy of meloxicam treatment for patients with sporadic desmoid tumors.

Authors:  Shunsuke Hamada; Hiroshi Urakawa; Eiji Kozawa; Naohisa Futamura; Kunihiro Ikuta; Yoshie Shimoyama; Shigeo Nakamura; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Tumour Biol       Date:  2014-01-05

6.  Prognostic factors for desmoid tumor: a surgical series of 233 patients at a single institution.

Authors:  Wei-Gen Zeng; Zhi-Xiang Zhou; Jian-Wei Liang; Hui-Rong Hou; Zheng Wang; Hai-Tao Zhou; Xing-Mao Zhang; Jun-Jie Hu
Journal:  Tumour Biol       Date:  2014-05-02

7.  Occurrence of an intrathoracic desmoid tumor following breast cancer treatment: A case report.

Authors:  Serkan Değirmencioğlu; Gokcen Demiray; Arzu Yaren; Ferda Bir; Duygu Herek
Journal:  Mol Clin Oncol       Date:  2015-12-08

8.  Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.

Authors:  Danielle Braggio; David Koller; Feng Jin; Nanda Siva; Abeba Zewdu; Gonzalo Lopez; Kara Batte; Lucia Casadei; Meng Welliver; Anne M Strohecker; Dina Lev; Raphael E Pollock
Journal:  Cancer       Date:  2019-04-12       Impact factor: 6.860

9.  MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours.

Authors:  Firouzeh Kamali; Wei-Lien Wang; B A Guadagnolo; Patricia S Fox; Valerae O Lewis; Alexander J Lazar; Anthony P Conley; Vinod Ravi; Mohammad Toliyat; Harshad S Ladha; Brian P Hobbs; Behrang Amini
Journal:  Br J Radiol       Date:  2015-11-18       Impact factor: 3.039

10.  Simple resection of truncal desmoid tumors: A case series.

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Hiroshi Urakawa; Shunsuke Hamada; Eiji Kozawa; Kunihiro Ikuta; Naoki Ishiguro
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.